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Background: Mainly single-agent chemotherapy has been consid-
ered as standard treatment for elderly patients with non-small cell
lung cancer (NSCLC). Docetaxel monotherapy is regarded as a
standard treatment for elderly patients with advanced NSCLC, and
recent subset analyses have suggested that platinum-based chemo-
therapy can be safely used in the elderly. This phase II study was
conducted to evaluate the efficacy and safety of docetaxel and
carboplatin in elderly patients with advanced NSCLC.
Methods: Patients enrolled in this study had stage IIIB or IV
NSCLC with measurable disease, no prior chemotherapy, Eastern
Cooperative Oncology Group performance status of 0–2, and were
70 years or older. Treatment consisted of docetaxel at a dose of 60
mg/m2 and carboplatin at area under the curve of 5 mg/ml/min on
day 1 every 3 weeks.
Results: From October 2003 to April 2006, 30 patients were
enrolled. One complete response and 13 partial responses were
observed, for an overall response rate of 46.7% (95% confidence
interval: 28.8–64.6%). Median progression-free survival and over-
all survival periods were 4.4 months and 9.9 months, respectively.
One-year survival rate was 43.3%. Major grade 3 and 4 hematolog-
ical toxicities included neutropenia (86.7%), leucopenia (80.0%) and
febrile neutropenia (16.7%). Major grade 3 nonhematological tox-
icities were anorexia (30.0%) and diarrhea (13.3%). There were no
grade 4 nonhematological toxicities or treatment-related deaths.
Conclusions: Docetaxel combined with carboplatin was an active
treatment with manageable toxicity for the treatment of elderly
patients with chemotherapy-naive NSCLC.
Key Words: Non-small cell lung cancer (NSCLC), Elderly patients,
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Lung cancer is a leading cause of cancer deaths in Europe,North America, and Japan. The risk of non-small cell lung
cancer (NSCLC) increases with age, and the prevalence of
NSCLC is expected to increase as the proportion of elderly
patients grows. In Japan, approximately 20% of the general
population was 65 years or older in 2005; by 2035, the elderly
population is estimated to reach 33%.1 Thus, determining the
optimal treatment strategy for NSCLC in elderly patients will
become a more important issue.
Compared with best supportive care, chemotherapy
improves survival and quality of life (QOL), and reduces
disease-related symptoms in patients with advanced
NSCLC.2 Platinum-based doublet regimens are the standard
of care for first-line chemotherapy in patients with advanced
NSCLC3,4; however, the effectiveness of these regimens in
elderly patients has not yet been proven. Platinum-based
doublet regimens involving newer agents, such as docetaxel,
paclitaxel, gemcitabine, vinorelbine, and irinotecan, are often
withheld from elderly patients due to tolerability concerns.
Optimal chemotherapy for elderly NSCLC patients has
been investigated in prospective randomized trials.5–7 The
Elderly Lung Cancer Vinorelbine Italian Study Group
showed increases in survival and QOL with single-agent
vinorelbine, compared with best supportive care.5 In the
multicenter Italian Lung Cancer in the Elderly Study, no
significant survival differences were observed with single-
agent vinorelbine, gemcitabine, or a vinorelbine-gemcitabine
combination.6 In our randomized phase III study of docetaxel
versus vinorelbine (the West Japan Thoracic Oncology Group
WJTOG trial 9904),7 docetaxel improved progression-free
survival (PFS), response rate, and disease-related symptoms.
Overall survival, however, was not significantly improved.
We concluded that docetaxel monotherapy should be consid-
ered as an option for first-line treatment in elderly patients
with advanced NSCLC.
Retrospective analyses of treatment outcomes with
platinum-based chemotherapy have shown that elderly pa-
tients are similar to younger patients in terms of response
rate, overall survival, toxicity, and QOL.8–10 However, the
retrospective subgroup analyses of elderly patients in these
randomized phase III trials only included highly selected
elderly patients with good performance status (PS) and with-
out significant comorbidity who fulfilled the rigorous inclu-
sion/exclusion criteria of the trials. These groups of patients
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do not represent the large heterogeneity of elderly patients
with different PS and comorbidities. Nevertheless, no pro-
spective phase III study of third-generation, single-agent
chemotherapy compared with the combination of a platinum
agent and a third-generation agent has been performed in
elderly patients with NSCLC.
The encouraging results of these age-specific analyses
and our own phase III study led us to design a prospective
phase II trial to evaluate the efficacy and safety of combining
docetaxel and carboplatin for the treatment of elderly patients
with advanced NSCLC. The primary end point of the study
was the response rate. Secondary endpoints included evalu-
ations of PFS, overall survival and safety.
PATIENTS AND METHODS
Eligibility Criteria
Patients aged 70 years or older with histologically or
cytologically confirmed NSCLC were enrolled. Eligible pa-
tients had measurable disease, stage IIIB (including only
patients with no indications for curative radiotherapy) or IV,
a PS of 0, 1 or 2 according to the Eastern Cooperative
Oncology Group scale, and an estimated life expectancy of at
least 12 weeks. Previous chemotherapy or radiotherapy was
not allowed, and adequate organ function was required (leu-
kocyte count 4000/l, neutrophil count 2000/l, platelet
count 100,000/l, hemoglobin concentration 9.5 g/dl,
total serum bilirubin 1.5 mg/dl, aspartate transaminase and
alanine aminotransferase 2.5 times the institutional upper
limit of normal, serum creatinine1.2 mg/dl, PaO270 torr,
and normal electrocardiograph). Patients were excluded for
any of the following reasons: myocardial infarction within the
previous 3 months, uncontrolled angina pectoris or arrhyth-
mia; symptomatic brain metastasis; uncontrolled hyperten-
sion or diabetes; active infection, pulmonary fibrosis, pleural
effusion or ascites requiring drainage; or cerebrovascular
disease. Written informed consent was obtained from all the
patients, and the ethics committee approved the protocol.
Patient Evaluation
The pretreatment evaluation consisted of a complete
blood cell count and routine chemistry measurements, chest
radiography, fiber-optic bronchoscopy, chest and abdominal
computed tomography scan, whole-brain magnetic resonance
imaging or computed tomography scan, and a radionuclide
bone scan. Laboratory tests were carried out once a week
during chemotherapy, and follow-up evaluations were re-
peated every cycle to evaluate tumor response.
Treatment Schedule
Docetaxel was administered at a dose of 60 mg/m2 over
1 hour by intravenous infusion. Immediately thereafter, car-
boplatin area under the curve (AUC) of 5 mg/ml/min was
administered intravenously over 1 hour. The dose of carbo-
platin was calculated using the Calvert formula, with the
creatinine clearance estimated using the Cockroft-Gault equa-
tion.11 Chemotherapy was administered every 21 days for at
least 4 cycles or until disease progression or unacceptable
toxicity occurred. All patients were premedicated with dexa-
methasone (20 mg, IV), ranitidine (50 mg, IV), diphenhydra-
mine (50 mg, orally), and a 5HT3 receptor antagonist. Pro-
phylactic use of recombinant granulocyte colony stimulating
factor (rhG-CSF) was not allowed in the first cycle but was
administered during subsequent cycles of chemotherapy fol-
lowing an episode of grade 4 neutropenia or grade 3 neutro-
penia with signs of infection. Chemotherapy was only admin-
istered if the patient had a leukocyte count 3000/l and a
platelet count 100,000/l. If the leukocyte count or platelet
count had not returned to these levels on day 1 of the next
cycle of chemotherapy, both drugs were withheld until full
recovery. Docetaxel and carboplatin doses were reduced by
10 mg/m2 and AUC 1, respectively, for any of the following
reasons: grade 4 neutropenia for 4 consecutive days or longer,
or grade 3 febrile neutropenia and/or thrombocytopenia.
Doses of docetaxel and carboplatin were also reduced in the
event of grade 3 or 4 nonhematological toxicities, excluding
nausea, vomiting, or anorexia.
Response and Toxicity Evaluation
Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines were used to evaluate antitumor activity. Toxicity
was graded according to the National Cancer Institute of Com-
mon Toxicity Criteria, version 3.0. The highest toxicity grade for
each patient in all cycles of chemotherapy was used for the
toxicity analysis.
Statistical Analysis
To determine the sample size, a Simon optimal two-
stage design was chosen.12 The null hypothesis for response
rates was 10%, with an alternative hypothesis of 30% at a
significance level of 0.05 and a statistical power of 80%. This
required 25 patients. If there were at least two responders
among the first 15 evaluable patients, then enrolment was to
have proceeded to a maximum of 25 patients. If at least 6 of
the 25 patients responded, then the null hypothesis would be
rejected. Overall survival was calculated from the start of
therapy to the date of last follow-up or death from any cause.
PFS was calculated from the start of therapy to the date of
disease progression, recurrence, or death from any cause.
Survival curves were estimated using the Kaplan-Meier
method.
RESULTS
Patient Characteristics
Between October 2003 and April 2006, 30 patients
were enrolled in this study. All patients were treated and
assessed for response, survival, and safety. The median age of
the patients was 75 years (range, 70–84 years). Baseline
characteristics are shown in Table 1. The majority of patients
had PS1 (76.7%) and comorbid illness (73.3%). Hypertension
(30.0%), liver disease (16.7%), and chronic pulmonary dis-
ease (13.3%) were the most common comorbid illnesses.
Most patients had stage IV disease (76.7%).
Treatment Delivery and Dose Intensity
The total number of treatment cycles delivered was 99,
and the median was 3.5 (range, 1–6). The frequency of dose
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reduction was 33.3% (10 of 30). Five patients received only
one cycle because of grade 3 febrile neutropenia (n  1),
pneumonitis (n  1), diarrhea (n  1), and disease progres-
sion (n  2). The planned dose intensities were 20.0 mg/
m2/wk for docetaxel and an AUC of 1.7 mg/ml/min/wk for
carboplatin; the actual median weekly dose intensities were
15.7 mg/m2 (78.5%) of docetaxel and an AUC of 1.3 mg/ml/
min (76.5%) for carboplatin. Four (4.0%) of the treatment
cycles were delayed by longer than 6 days due to toxicity.
Safety
Table 2 lists the incidence of hematological and non-
hematological toxicities. Grade 3–4 neutropenia and leuco-
penia were the most common adverse events and occurred in
86.7 and 80.0% of the patients, respectively. The median
duration of grade 4 neutropenia was 2 days, and the range
was 1 to 7 days. During treatment, 25 (83.3%) patients
received rhG-CSF, although only 5 (16.7%) patients had
febrile neutropenia. One patient was given a red blood cell
transfusion, but none of the patients needed platelet transfu-
sions. Grade 3 nonhematological adverse events occurred in
17 (56.7%) patients, including anorexia in 9 (30.0%), diar-
rhea in 4 (13.3%), nausea in 3 (10.0%), infection in 3
(10.0%), fatigue in 2 (6.7%), allergic reactions in 2 (6.7%),
and pneumonitis in 1 (3.3%). Neither grade 4 nonhemato-
logical toxicities nor evidence of cumulative toxicity were
observed. No treatment-related deaths occurred.
Efficacy
All the patients were evaluable for response evaluation.
One complete response and 13 partial responses were re-
corded, with an overall response rate of 46.7% (95% confi-
dence interval CI: 28.8–64.6%). The period of one com-
plete response case was 19.6 months. With a median
follow-up period of 8.4 months, the median PFS was 4.4
months (95% CI: 3.4–5.4 months) and the median overall
survival period was 9.9 months (95% CI: 7.6–12.2 months)
(Figure 1). The 1-year survival rate was 43.3%.
The most frequent sites of progression were primary
site (46.7%) and metastases to the brain (13.3%). Eleven
(36.7%) patients received second-line chemotherapy. Five
patients (16.7%) were treated with gefitinib, 2 patients (6.7%)
were treated with gemcitabine, and 1 patient each was treated
with paclitaxel, pemetrexed, amrubicin, and vinorelbine
(3.3% each).
DISCUSSION
In this article, the combination of carboplatin and
tri-weekly docetaxel in elderly patients with advanced
NSCLC was evaluated. Our results show that this regimen is
active, resulting in an overall response rate of 46.7%, a
median PFS of 4.4 months, and a median survival of 9.9
months. Although the toxicities in our study were manage-
able, the combination of docetaxel and carboplatin resulted in
TABLE 1. Patient Characteristics
Characteristics
Present study (n  30)
No. of patients (%)
Gender
Male 20 66.7
Female 10 33.3
ECOG performance status
0 2 6.7
1 23 76.7
2 5 16.7
Stage
IIIB 7 23.3
IV 23 76.7
Histology
Adenocarcinoma 23 76.7
Squamous cell carcinoma 6 20
Other 1 3.3
Prior therapy
Surgery 6 20
WBRT 1 3.3
None 23 76.7
Smoking
Smoker 24 80
Never smoker 6 20
Weight loss
10% 5 16.6
10% 25 83.3
Comorbid illness
Yes 22 73.3
No 8 26.7
ECOG, Eastern Cooperative Oncology Group; WBRT, whole brain radiation
therapy.
TABLE 2. Toxicity in All Cycles (n  30)
Toxicity
Grade Grade
1 2 3 4 3/4 3/4 (%)
Leucopenia 2 4 19 5 24 80.0
Neutropenia 0 3 8 18 26 86.7
Febrile neutropenia — — 5 0 5 16.7
Thrombocytopenia 18 5 1 0 1 3.3
Anemia 9 14 5 0 5 16.7
Infection — 0 3 0 3 10.0
Pneumonitis 0 0 1 0 1 3.3
Nausea 13 5 3 0 3 10.0
Vomiting 9 2 0 0 0 0.0
Anorexia 10 11 9 0 9 30.0
Diarrhea 6 6 4 0 4 13.3
Constipation 9 3 0 0 0 0.0
Neuropathy 4 0 0 0 0 0.0
Fatigue 18 10 2 0 2 6.7
Alopecia 4 23 — — — —
Allergic reaction 0 0 2 0 2 6.7
AST 14 0 0 0 0 0.0
ALT 10 0 0 0 0 0.0
Alkaline phosphatase 8 2 0 0 0 0.0
Total bilirubin 4 4 0 0 0 0.0
Creatinine 5 0 0 0 0 0.0
AST, aspartate transaminase; ALT, alanine aminotransferase.
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higher rates of grade 3/4 leucopenia (80.0 versus 58.0%),
grade 3 febrile neutropenia (16.7 versus 12.5%), grade 3/4
anemia (16.7 versus 3.4%), and grade 3 diarrhea (13.3 versus
4.5%), compared with our previous WJTOG 9904 trial of
single-agent docetaxel in a similar population of patients.7 To
carefully manage toxicity, the frequency of rhG-CSF use
(83.3%) was comparatively high; however, we were able to
shorten the period of grade 4 neutropenia (median: 2 days,
range: 1–7 days) and were able to manage the patients while
monitoring for infectious disease. The rates of other toxicities
and the median number of treatment cycles delivered (3.5
versus 4) were similar in the two studies. Therefore, the
combination of docetaxel and carboplatin has an acceptable
toxicity profile, when compared with single-agent docetaxel.
However, patients with concomitant infection (common in
frail patients with lung cancer) should be treated with extreme
caution.
In the docetaxel arm of WJTOG 9904, overall response
rate was 22.7%, median PFS was 5.5 months, median sur-
vival was 14.3 months, and 1-year survival was 58.6%.7 In
our study, the addition of carboplatin appeared to improve the
overall response rate to 46.7% (95% CI: 28.8–64.6%), but a
survival benefit was not observed compared with the do-
cetaxel arm in WJTOG 9904. One reason for this discrepancy
may have been the difference in the patient selection criteria.
In the WJTOG 9904 trial, PS 2 patients were excluded, and
only 1 patient (1.1%) with PS 2 was enrolled in the docetaxel
arm; whereas in our study, 5 patients (16.7%) had PS 2.
Another reason may be the difference in clinical stage. In the
WJTOG 9904 trial, 56 patients (62.9%) were stage IV, while
23 patients (76.7%) were stage IV in our study. The fact that
more patients with poor prognostic factors were enrolled in
our study may explain the apparent lack of improvement in
survival after combination therapy. Nevertheless, such ques-
tions can be addressed only through a randomized trial.
Four prospective randomized studies of chemotherapy
in elderly patients with advanced NSCLC have been pub-
lished. Italian investigators conducted three trials 5,6,13 and we
compared docetaxel to vinorelbine for elderly patients with
advanced NSCLC (WJTOG 9904).7 None of these studies
evaluated platinum-based chemotherapy. Platinum-contain-
ing chemotherapy is standard for younger patients based on
the results of several randomized studies.3,4,14,15 In elderly
patients, only subgroup analyses of platinum-based chemo-
therapy have been reported.8,9,10,16,17 These studies showed
similar outcomes of platinum-based therapy for elderly pa-
tients and for younger patients in terms of response rate and
overall survival, with similar toxicities and no significant
adverse effects on QOL.
Lilenbaum et al.18 compared the efficacy of combina-
tion chemotherapy versus single-agent therapy in patients
with advanced NSCLC. A total of 561 eligible patients were
randomly assigned to receive either paclitaxel alone or in
combination with carboplatin. Combination chemotherapy
improved response rate and failure-free survival compared
with single-agent therapy, but there was no statistically sig-
nificant difference in the primary end point of overall sur-
vival. For elderly patients, the 1-year survival rate for com-
bination chemotherapy was 35%, compared with 31% for
single-agent therapy (hazard ratio  0.84, p  0.29).
FIGURE 1. Kaplan-Meier survival curve (__) and time to tumor progression curve (…) for the 30 assessable patients. The progres-
sion-free survival, median survival time, and 1-year survival rate were 4.4 months, 9.9 months, and 43.3%, respectively. The sym-
bols (l) represent censored patients.
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At present, there are no prospective phase III studies
comparing platinum added to third-generation single agents
in elderly patients with NSCLC. We have, in this study,
demonstrated the feasibility and primary response rate of
docetaxel combined with carboplatin; therefore, the next step
would be to compare this regimen to docetaxel monotherapy
in a phase III trial.
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